Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer Meeting Abstract
| Authors: | Maurer, D.; Yu, J. X.; Sklodowski, K.; Tognetti, M.; Reiter, L.; Bruderer, R.; Vowinckel, J.; Pfeiffer, S.; O'Hara, M.; O'Reilly, E.; Wolff, R.; Wainberg, Z.; Ko, A.; Rahm, O.; Fisher, G.; Lyman, J.; Cabanski, C.; Gherardini, P. F.; O'Donnell-Tormey, J.; LaVallee, T.; Vonderheide, R.; Kitch, L. |
| Abstract Title: | Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer |
| Meeting Title: | 36th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2021) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 9 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Nov 10-14 |
| Meeting Location: | Washington, DC |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2021-11-01 |
| Start Page: | A370 |
| Language: | English |
| ACCESSION: | WOS:000774877500332 |
| DOI: | 10.1136/jitc-2021-SITC2021.343 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 343 -- Meeting was also presented virtually -- Source: Wos |
